DelveInsight's Hepatocellular Carcinoma Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM. LAS VEGAS, NV, UNITED STATES, January 20, 2025 ...
PRINCETON, N.J. - Bristol Myers Squibb (NYSE: BMY), a prominent pharmaceutical company with a market capitalization of nearly $120 billion and impressive gross profit margins of 76%, received a ...
The US Food and Drug Administration has granted orphan drug designation (ODD) to Tempest Therapeutics' oral, selective ...
Market Trends Hepatocellular carcinoma is the third most common cause of cancer-related deaths globally. The market for HCC was valued at $780 million in 2023 and is expected to increase to grow ...
Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...
Coherus BioSciences (CHRS) announced final data from its Phase 2 open label clinical trial evaluating casdozokitug, a selective and potent ...
Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...
Hepatocellular carcinoma is a rapidly progressing cancer that occurs in the liver. Last October, Tempest announced a collaboration with Roche to further assess amezalpat in conjunction with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback